Laidlaw Upgrades Intercept Pharmaceuticals (ICPT) to Buy

Laidlaw analyst Francois Brisebois upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Neutral to Buy with a price target of $130.00 (from $99.00).

The analyst comments "...we were encouraged by ICPT’s announcement of its acquisition of Aralez Pharmaceuticals’ license to develop and commercialize bezafibrate (PPAR agonist) in the US, its IND on file with the FDA as well as other associated regulatory documentation and a non-exclusive license to certain of Aralez’s IP. ICPT plans to start a Phase 2 to evaluate a combination of bezafibrate + OCA in PBC patients."

For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.

Shares of Intercept Pharmaceuticals closed at $109.05 yesterday.

You May Also Be Interested In

• New Street Research Upgrades Micron Technology (MU) to Buy
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
• Petronet LNG Ltd. (PLNG:IN) PT Raised to INR310 at ICICI Securities